Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
General Internal Medicine
•
Rheumatology
•
Hematology
•
Pediatric Hematology
•
Lupus nephritis
•
Antiphospholipid Syndrome
•
Nephrology
•
Glomerulonephritis
•
Anticoagulation
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Related Questions
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
How would you approach pursuing a kidney biopsy in a patient with suspected lupus nephritis who is on warfarin for antiphospholipid antibody syndrome?
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
How do you manage arthritis resulting from deferiprone in transfusion dependent thalassemia?
What is your threshold to repeat a kidney biopsy in a patient with a history of lupus nephritis who is on maintenance therapy and develops subtle changes in urinary protein excretion or microscopic hematuria?
Can lupus anticoagulant be positive despite a normal aPTT?
What is your treatment approach when managing patients with relapsing lupus nephritis who previously achieved remission with mycophenolate and steroids?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
How should clinicians approach the decision to use apixaban, or other DOACs, in pediatric patients with acute lymphoblastic leukemia or lymphoma who have additional risk factors for VTE, such as obesity or a family history of thrombosis, given the negative outcome of the PREVAPIX-ALL trial?